Marshall Urist, EVP of Research and Investments at Royalty Pharma plc, filed a Form 4 on November 18, 2026, disclosing the sale of 25,000 Class A Ordinary Shares on November 16, 2026, under a Rule 10b5-1 plan.
Key Highlights
- Reporting person: Marshall Urist, EVP, Research and Investments at Royalty Pharma plc (NASDAQ:RPRX)
- Shares sold: 23,592 Class A Ordinary Shares at a weighted average price of $69.4701, and 1,408 Class A Ordinary Shares at a weighted average price of $69.9941, both on November 16, 2026
- Price ranges: First sale ranged from $68.93 to $69.92 per share; second sale ranged from $69.92 to $70.00 per share
- Shares held after transactions: 125,000 Class A Ordinary Shares held indirectly through Sandy Lamm LLC, plus 19,020 held indirectly by IRA and 5,341 held directly
- 10b5-1 plan: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 7, 2026
- Additional holdings: The reporting person and family vehicles hold limited partnership interests exchangeable into 2,294,120 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,356,528 Class A Ordinary Shares
Urist's November 16 Sales Under Pre-Established Trading Plan
According to the filing, Marshall Urist, who serves as EVP of Research and Investments at Royalty Pharma plc (NASDAQ:RPRX), disposed of a combined 25,000 Class A Ordinary Shares on November 16, 2026, in two separate transactions. Both transactions were carried out through Sandy Lamm LLC, an entity through which Urist holds shares indirectly. The filing notes that all reported transactions were effected pursuant to a Rule 10b5-1 plan adopted on August 7, 2026.
The first transaction involved 23,592 shares sold at a weighted average price of $69.4701, with individual sale prices ranging from $68.93 to $69.92 per share. The second transaction covered 1,408 shares at a weighted average price of $69.9941, with prices ranging from $69.92 to $70.00 per share. The filing states that full information on the number of shares sold at each separate price within those ranges is available upon written request to the issuer, any security holder, or the SEC staff.
Following the reported transactions, the filing discloses that Urist beneficially owns 125,000 Class A Ordinary Shares indirectly through Sandy Lamm LLC, 19,020 Class A Ordinary Shares indirectly through an IRA, and 5,341 Class A Ordinary Shares directly. The filing also notes, in the Remarks section, that the reporting person and family vehicles controlled by the reporting person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,294,120 Class A Ordinary Shares, and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,356,528 Class A Ordinary Shares, with Class E Ordinary Shares subject to vesting conditions.
What Was Disclosed
The Form 4 filed November 18, 2026, discloses two sales of Class A Ordinary Shares by Marshall Urist totaling 25,000 shares on November 16, 2026, both executed under a pre-established 10b5-1 trading plan through Sandy Lamm LLC.





Please wait processing your request...